Vericel Corp

VCEL

Vericel Corp

VCEL

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-26Shares Purchased (TTM):0Shares Sold (TTM):183,879

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:52,747,963Shares Outstanding:50,773,000Institutional Ownership Pct.:103.89%

Earnings Market Reaction:

Filing Date:2026-07-30Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	125	109	100	100	81	73	75	54	50	63	69	60
Restricted Cash Current	-	-	0	0	0	6	11	17	26	8	18	23
Short Term Investments	37	36	37	35	36	39	42	48	52	48	40	45
Accounts Receivable Net Current	76	72	85	60	64	53	61	48	48	50	58	40
Inventory Net	18	18	18	18	17	17	17	16	15	14	13	13
Other Assets Current	8	8	8	8	7	9	7	8	6	8	7	5
Assets Current	265	244	247	222	205	198	213	191	197	190	206	186
Property Plant And Equipment And Finance Lease Rig…	106	107	108	109	110	108	103	88	73	56	42	30
Finite Lived Intangible Assets Net	5	5	6	6	6	6	6	6	7	7	7	7
Operating Lease Right Of Use Asset	62	63	65	66	67	69	70	72	73	74	73	73
Available For Sale Securities Debt Securities Nonc…	65	65	61	50	47	43	40	33	26	29	25	20
Other Assets Noncurrent	0	0	0	0	0	1	1	1	1	1	1	1
Assets	503	486	488	453	436	425	433	390	377	357	354	318
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	21	19	16	15	13	17	24	21	25	19	22	15
Accrued Liabilities Current	18	14	19	16	14	11	17	14	13	11	17	14
Operating Lease Liability Current	14	14	14	14	14	11	9	6	6	6	6	7
Other Liabilities Current	0	0	0	0	0	0	0	-	-	-	0	0
Liabilities Current	53	47	49	46	41	39	50	41	44	36	46	36
Operating Lease Liability Noncurrent	78	80	82	84	86	88	90	91	90	86	82	78
Other Liabilities Noncurrent	2	2	2	2	2	2	1	0	0	0	0	0
Liabilities	133	129	133	131	129	129	141	133	134	123	128	114
Stockholders Equity
Common Stock Value	751	739	731	721	711	699	685	670	655	641	629	621
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	0	0	0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-380	-383	-376	-400	-405	-404	-393	-413	-412	-407	-403	-416
Stockholders Equity	370	356	355	322	307	295	292	257	243	234	226	204
Liabilities And Stockholders Equity	503	486	488	453	436	425	433	390	377	357	354	318
Allowance For Doubtful Accounts Receivable Current	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	75	75	75	75	75	75	75	75	75	75	75	75
Common Stock Shares Issued	51	51	51	51	50	50	50	49	49	48	48	48
Shares Outstanding	51	51	51	51	50	50	50	49	49	48	48	48

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-5.12%	31.60%	28.24%	-	-	-	-	-	-	-	-	-
2025	-1.36%	-0.33%	-4.18%	5.98%	-9.33%	1.09%	3.87%	-2.81%	-2.32%	-16.64%	-5.31%	-12.34%
2024	0.02%	-3.80%	9.71%	3.72%	-2.00%	-12.33%	16.21%	14.59%	14.79%	-6.77%	-16.91%	-14.39%
2023	-	-	-	-6.21%	-1.82%	-4.16%	0.99%	0.96%	20.78%	2.67%	-4.25%	5.85%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.04	5.18	5.03	4.87	4.97	5.01	4.23	4.61	4.50	5.20	4.49	5.18
Quick Ratio	4.69	4.79	4.68	4.47	4.56	4.58	3.89	4.23	4.16	4.83	4.21	4.83
Working Capital	212.20M	196.91M	198.29M	176.39M	163.45M	158.19M	162.49M	149.17M	153.52M	153.25M	159.88M	150.27M
Leverage & Debt
Debt to Equity	0.36	0.36	0.38	0.41	0.42	0.44	0.48	0.52	0.55	0.52	0.57	0.56
Interest Coverage TTM	28.49	24.76	17.53	11.43	1.93	-4.57	7.36	-2.00	-6.24	-6.17	-10.77	-19.66
Debt Ratio	0.26	0.27	0.27	0.29	0.30	0.30	0.33	0.34	0.36	0.34	0.36	0.36
Efficiency & Turnover
Asset Turnover TTM	0.65	0.64	0.60	0.61	0.61	0.61	0.60	0.64	0.62	0.67	0.63	0.65
Days Sales Outstanding TTM	83.42	78.28	96.46	76.82	82.26	78.67	92.11	70.96	73.43	77.55	96.92	73.03
Receivables Turnover TTM	4.38	4.66	3.78	4.75	4.44	4.64	3.96	5.14	4.97	4.71	3.77	5.00
Per Share Metrics
Diluted EPS TTM	0.46	0.42	0.32	0.25	0.14	0.06	0.20	0.07	0.02	0.01	-0.07	-0.22
Free Cash Flow Per Share TTM	1.06	0.79	0.49	0.23	-0.34	-0.31	-0.23	-0.10	0.10	0.19	0.20	0.33
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	74.56%	74.84%	74.42%	73.81%	73.47%	72.54%	72.55%	71.47%	70.42%	69.50%	68.64%	67.74%
Operating Profit Margin TTM	5.95%	5.40%	4.00%	2.75%	0.48%	-1.18%	1.90%	-0.54%	-1.78%	-1.81%	-3.27%	-7.09%
Net Profit Margin TTM	7.91%	7.35%	5.98%	5.06%	2.85%	1.25%	4.37%	1.56%	0.37%	0.22%	-1.61%	-5.54%
Growth Metrics
Net Revenue Growth (1Y)	22.95%	22.45%	16.45%	14.05%	16.13%	14.80%	20.10%	22.62%	20.70%	23.21%	20.66%	18.09%
Net Income Growth (1Y)	240.80%	620.69%	59.41%	268.71%	800.76%	560.31%	-425.64%	-134.60%	-105.99%	-102.64%	-80.96%	-43.34%
EPS Growth (1Y)	236.09%	608.36%	54.68%	258.46%	770.68%	536.97%	-417.26%	-133.59%	-105.85%	-102.59%	-81.14%	-43.90%
Valuation Metrics
P/E TTM	93.82	76.11	109.74	121.46	301.56	747.74	258.85	584.51	2,831.07	5,552.76	-532.58	-155.78
P/B TTM	6.14	4.59	5.11	4.94	6.99	7.54	9.19	8.05	9.19	10.71	7.50	7.81
P/S TTM	7.42	5.59	6.56	6.14	8.60	9.33	11.31	9.14	10.41	12.05	8.58	8.63
Market Cap	2.27B	1.63B	1.81B	1.59B	2.14B	2.23B	2.68B	2.07B	2.23B	2.50B	1.69B	1.60B
Enterprise Value	2.15B	1.52B	1.71B	1.49B	2.06B	2.15B	2.61B	2.00B	2.18B	2.43B	1.61B	1.51B
Calculated Values
Free Cash Flow TTM	54.11M	39.94M	24.75M	11.75M	-16.93M	-15.24M	-11.30M	-4.94M	4.89M	9.11M	9.73M	15.55M
Net Debt	-125.36M	-109.30M	-100.09M	-100.40M	-80.53M	-79.71M	-74.52M	-70.35M	-50.29M	-70.74M	-86.87M	-83.56M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-26Sale

Owner: Mara, Joseph Anthony Jr

Title: Chief Financial Officer

Shares: 5,000

Price/Share: $44.75

Value: $223,750.00

Shares Owned: 16,009

Relationship: Officer

Ownership: Direct

2026-06-26Sale

Owner: Siegal, Jonathan

Title: Principal Accounting Officer

Shares: 2,732

Price/Share: $44.90

Value: $122,666.80

Shares Owned: 886

Relationship: Officer

Ownership: Direct

2026-06-26Sale

Owner: Flynn, Sean C.

Title: Chief Legal Officer

Shares: 15,000

Price/Share: $45.64

Value: $684,600.00

Shares Owned: 1,647

Relationship: Officer

Ownership: Direct

2026-06-26Sale

Owner: Hopper, Jonathan Mark

Title: Chief Medical Officer

Shares: 10,000

Price/Share: $45.00

Value: $450,000.00

Shares Owned: 75,753

Relationship: Officer

Ownership: Direct

2026-06-18Sale

Owner: Flynn, Sean C.

Title: Chief Legal Officer

Shares: 15,000

Price/Share: $40.21

Value: $603,150.00

Shares Owned: 1,647

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-26	Mara, Joseph Anthony Jr	Officer	Chief Financial Officer	Direct	Sale	5,000	44.75	$223,750.00	16,009	4
2026-06-26	Siegal, Jonathan	Officer	Principal Accounting Officer	Direct	Sale	2,732	44.90	$122,666.80	886	4
2026-06-26	Flynn, Sean C.	Officer	Chief Legal Officer	Direct	Sale	15,000	45.64	$684,600.00	1,647	4
2026-06-26	Hopper, Jonathan Mark	Officer	Chief Medical Officer	Direct	Sale	10,000	45.00	$450,000.00	75,753	4
2026-06-18	Flynn, Sean C.	Officer	Chief Legal Officer	Direct	Sale	15,000	40.21	$603,150.00	1,647	4
2026-06-18	Halpin, Michael	Officer	Chief Operating Officer	Direct	Sale	10,000	40.24	$402,400.00	16,248	4
2026-06-02	Hopper, Jonathan Mark	Officer	Chief Medical Officer	Direct	Sale	4,375	35.00	$153,125.00	75,753	4
2026-05-13	Mclaughlin, Kevin F	Director	-	Direct	Sale	7,000	32.83	$229,810.00	18,300	4
2026-05-11	Wotton, Paul K	Director	-	Direct	Sale	10,000	32.84	$328,400.00	18,802	4
2026-05-07	Mara, Joseph Anthony Jr	Officer	Chief Financial Officer	Direct	Sale	5,000	40.50	$202,500.00	21,009	4
2026-05-07	Siegal, Jonathan	Officer	Principal Accounting Officer	Direct	Sale	1,422	40.50	$57,591.00	1,118	4
2026-04-02	Hopper, Jonathan Mark	Officer	Chief Medical Officer	Direct	Sale	3,472	35.00	$121,520.00	75,556	4
2026-03-23	Hagen, Heidi	Director	-	Direct	Sale	15,000	32.41	$486,150.00	31,850	4
2026-03-02	Halpin, Michael	Officer	Chief Operating Officer	Direct	Sale	10,305	35.30	$363,766.50	16,080	4
2026-03-02	Flynn, Sean C.	Officer	Chief Legal Officer	Direct	Sale	21,421	35.06	$751,020.26	1,262	4
2026-02-11	Mclaughlin, Kevin F	Director	-	Direct	Sale	7,000	34.66	$242,620.00	15,100	4
2026-01-07	Halpin, Michael	Officer	Chief Operating Officer	Direct	Sale	10,000	40.48	$404,800.00	16,080	4
2025-12-03	Wotton, Paul K	Director	-	Direct	Sale	2,500	37.83	$94,575.00	25,602	4
2025-12-02	Hopper, Jonathan Mark	Officer	Chief Medical Officer	Direct	Sale	1,652	39.14	$64,659.28	66,562	4
2025-11-11	Halpin, Michael	Officer	Chief Operating Officer	Direct	Sale	2,642	40.41	$106,763.22	15,932	4
2025-11-10	Mclaughlin, Kevin F	Director	-	Direct	Sale	7,000	38.59	$270,130.00	15,100	4
2025-11-06	Halpin, Michael	Officer	Chief Operating Officer	Direct	Sale	7,358	40.47	$297,778.26	15,932	4
2025-09-02	Hopper, Jonathan Mark	Officer	Chief Medical Officer	Direct	Sale	10,000	35.77	$357,700.00	66,363	4
2025-08-06	Mclaughlin, Kevin F	Director	-	Direct	Sale	7,000	35.92	$251,440.00	15,100	4
2025-06-02	Hopper, Jonathan Mark	Officer	Chief Medical Officer	Direct	Sale	10,000	40.09	$400,900.00	66,237	4
2025-05-15	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	14,063	41.53	$584,036.39	260,354	4
2025-05-07	Mclaughlin, Kevin F	Director	-	Direct	Sale	7,000	39.98	$279,860.00	15,100	4
2025-04-10	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	24,850	41.89	$1,040,966.50	260,354	4
2025-03-13	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	26,592	45.78	$1,217,381.76	259,997	4
2025-03-03	Mara, Joseph Anthony Jr	Officer	Chief Financial Officer	Direct	Sale	9,000	49.53	$445,770.00	13,967	4
2025-03-03	Hagen, Heidi	Director	-	Direct	Sale	9,000	49.53	$445,770.00	28,650	4
2025-03-03	Hopper, Jonathan Mark	Officer	Chief Medical Officer	Direct	Sale	10,000	49.53	$495,300.00	66,101	4
2025-03-03	Halpin, Michael	Officer	Chief Operating Officer	Direct	Sale	10,000	49.52	$495,200.00	15,539	4
2025-02-25	Siegal, Jonathan	Officer	Principal Accounting Officer	Direct	Sale	1,137	52.07	$59,203.59	1,206	4
2025-02-25	Flynn, Sean C.	Officer	Chief Legal Officer	Direct	Sale	1,669	52.07	$86,904.83	756	4
2025-02-20	Flynn, Sean C.	Officer	Chief Legal Officer	Direct	Sale	3,835	57.32	$219,822.20	756	4
2025-02-19	Siegal, Jonathan	Officer	Principal Accounting Officer	Direct	Sale	1,710	56.72	$96,991.20	1,206	4
2025-02-12	Mclaughlin, Kevin F	Director	-	Direct	Sale	7,000	55.45	$388,150.00	11,900	4
2025-02-05	Zerbe, Robert L Md	Director	-	Direct	Sale	2,500	62.50	$156,250.00	26,595	4
2025-02-05	Siegal, Jonathan	Officer	Principal Accounting Officer	Direct	Sale	1,092	61.99	$67,693.08	1,206	4
2025-01-28	Siegal, Jonathan	Officer	Principal Accounting Officer	Direct	Sale	3,908	61.99	$242,256.92	1,206	4
2024-12-04	Wotton, Paul K	Director	-	Direct	Sale	2,600	58.72	$152,672.00	27,402	4
2024-12-02	Hopper, Jonathan Mark	Officer	Chief Medical Officer	Direct	Sale	10,000	58.72	$587,200.00	58,371	4
2024-11-22	Zerbe, Robert L Md	Director	-	Direct	Sale	2,500	60.00	$150,000.00	26,595	4
2024-11-14	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	17,500	53.93	$943,775.00	220,937	4
2024-11-13	Mclaughlin, Kevin F	Director	-	Direct	Sale	7,000	55.54	$388,780.00	11,900	4
2024-11-12	Zerbe, Robert L Md	Director	-	Direct	Sale	2,500	57.50	$143,750.00	26,595	4
2024-10-17	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	17,500	40.34	$705,950.00	220,937	4
2024-10-16	Gilman, Steven C	Director	-	Direct	Sale	5,833	41.36	$241,252.88	11,000	4
2024-10-02	Gilman, Steven C	Director	-	Direct	Sale	5,833	40.35	$235,361.55	11,000	4
2024-10-01	Siegal, Jonathan	Officer	Principal Accounting Officer	Direct	Sale	568	41.90	$23,799.20	1,124	4
2024-09-18	Gilman, Steven C	Director	-	Direct	Sale	5,834	45.54	$265,680.36	11,000	4
2024-09-12	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	17,500	43.90	$768,250.00	220,937	4
2024-09-04	Gilman, Steven C	Director	-	Direct	Sale	5,000	48.58	$242,900.00	11,000	4
2024-09-03	Hopper, Jonathan Mark	Officer	Chief Medical Officer	Direct	Sale	10,000	49.83	$498,300.00	58,229	4
2024-08-15	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	17,500	46.24	$809,200.00	220,937	4
2024-08-07	Mclaughlin, Kevin F	Director	-	Direct	Sale	7,000	45.96	$321,720.00	11,900	4
2024-07-18	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	17,500	51.40	$899,500.00	220,937	4
2024-07-16	Flynn, Sean C.	Officer	Chief Legal Officer	Direct	Sale	15,000	52.18	$782,700.00	707	4
2024-07-12	Mara, Joseph Anthony Jr	Officer	Chief Financial Officer	Direct	Sale	5,000	50.00	$250,000.00	14,436	4
2024-07-05	Siegal, Jonathan	Officer	Principal Accounting Officer	Direct	Sale	545	45.00	$24,525.00	1,033	4
2024-06-24	Flynn, Sean C.	Officer	Chief Legal Officer	Direct	Sale	1,474	45.84	$67,568.16	487	4
2024-06-13	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	17,500	43.10	$754,250.00	220,752	4
2024-05-20	Hopper, Jonathan Mark	Officer	Chief Medical Officer	Direct	Sale	10,000	49.99	$499,900.00	58,116	4
2024-05-16	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	17,500	47.85	$837,375.00	220,752	4
2024-04-18	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	17,500	44.59	$780,325.00	195,307	4
2024-03-27	Zerbe, Robert L Md	Director	-	Direct	Sale	3,278	51.57	$169,046.46	23,395	4
2024-03-14	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	17,500	44.02	$770,350.00	194,870	4
2024-03-11	Halpin, Michael	Officer	Chief Operating Officer	Direct	Sale	7,874	44.71	$352,046.54	949	4
2024-03-08	Flynn, Sean C.	Officer	SVP, General Counsel	Direct	Sale	8,115	45.33	$367,852.95	167	4/A
2024-03-07	Siegal, Jonathan	Officer	Principal Accounting Officer	Direct	Sale	1,634	45.00	$73,530.00	1,400	4
2024-02-20	Zerbe, Robert L Md	Director	-	Direct	Sale	722	50.01	$36,107.22	23,395	4
2024-02-15	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	17,500	48.85	$854,875.00	174,008	4
2024-01-29	Zerbe, Robert L Md	Director	-	Direct	Sale	2,300	44.22	$101,706.00	23,395	4
2024-01-25	Zerbe, Robert L Md	Director	-	Direct	Sale	200	44.02	$8,804.00	25,695	4
2024-01-22	Zerbe, Robert L Md	Director	-	Direct	Sale	8,000	41.83	$334,640.00	25,895	4
2024-01-18	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	16,726	38.58	$645,289.08	169,985	4
2024-01-12	Zerbe, Robert L Md	Director	-	Direct	Sale	2,200	38.09	$83,798.00	30,895	4
2023-12-14	Flynn, Sean C.	Officer	SVP, General Counsel	Direct	Sale	106	37.45	$3,969.70	4,467	4
2023-12-14	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	12,000	37.12	$445,440.00	169,985	4
2023-12-14	Wotton, Paul K	Director	-	Direct	Sale	5,000	37.31	$186,550.00	26,802	4
2023-12-07	Colangelo, Dominick	Director,Officer	President and CEO	Direct	Sale	12,000	33.84	$406,080.00	176,742	4
2023-11-30	Halpin, Michael	Officer	Chief Operating Officer	Direct	Sale	17,447	35.41	$617,798.27	827	4
2023-11-20	Hopper, Jonathan Mark	Officer	Chief Medical Officer	Direct	Sale	5,000	36.40	$182,000.00	53,007	4
2023-11-15	Siegal, Jonathan	Officer	Principal Accounting Officer	Direct	Sale	662	37.70	$24,957.40	1,305	4
2023-11-15	Zerbe, Robert L Md	Director	-	Direct	Sale	300	38.03	$11,409.00	33,095	4
2023-07-14	Zerbe, Robert L Md	Director	-	Direct	Sale	1,000	38.84	$38,840.00	33,395	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

103.89%

Inst. Shares: 52,747,963

Shares Outstanding: 50,773,000

2025-12-31

99.16%

Inst. Shares: 49,918,209

Shares Outstanding: 50,340,000

2025-09-30

98.67%

Inst. Shares: 49,816,537

Shares Outstanding: 50,489,000

2025-06-30

100.91%

Inst. Shares: 50,823,884

Shares Outstanding: 50,368,000

2025-03-31

95.99%

Inst. Shares: 47,902,822

Shares Outstanding: 49,905,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	52,747,963	50,773,000	103.89%
2025-12-31	49,918,209	50,340,000	99.16%
2025-09-30	49,816,537	50,489,000	98.67%
2025-06-30	50,823,884	50,368,000	100.91%
2025-03-31	47,902,822	49,905,000	95.99%
2024-12-31	46,606,570	48,848,000	95.41%
2024-09-30	45,136,221	49,085,000	91.96%
2024-06-30	44,743,939	48,686,000	91.90%
2024-03-31	44,688,901	48,141,000	92.83%
2023-12-31	45,492,520	47,590,000	95.59%
2023-09-30	45,208,228	47,649,000	94.88%
2023-06-30	42,357,900	47,572,000	89.04%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Vericel Corp (VCEL) — SEC Financial Statements & Analysis

Vericel Corp (VCEL) is a biological products, (no diagnostic substances) company, incorporated in MI. Vericel Corp trades on Nasdaq as: VCEL. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Vericel Corp reported a 22.95% year-over-year revenue growth, a Gross Profit Margin of 74.56% (TTM), a Debt-to-Equity ratio of 0.36x, a Price-to-Sales (P/S) ratio of 7.42x (TTM), a Price-to-Book (P/B) ratio of 6.14x (TTM), at a market cap of $2.27B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 22.95%
Gross Profit Margin TTM: 74.56%
Debt To Equity: 0.36x
P/S TTM: 7.42x
P/B TTM: 6.14x
Market Cap: $2.27B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Vericel Corp in?

Vericel Corp (VCEL) operates in the Biological Products, (No Diagnostic Substances) industry.

What is VCEL's market cap?

Vericel Corp (VCEL) has a market capitalization of $2.27B as of 2026-06-30.

What is VCEL's P/E ratio?

Vericel Corp (VCEL)'s trailing twelve month P/E ratio is 93.82x as of 2026-06-30.

What exchange does VCEL trade on?

Vericel Corp (VCEL) trades on the Nasdaq.

Where is Vericel Corp incorporated?

Vericel Corp is incorporated in MI.

Vericel Corp

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Vericel Corp (VCEL) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.
Main Street's price.

Vericel Corp (VCEL) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.